Natural History of Levodopa-Induced Dyskinesia (LID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01003002|
Recruitment Status : Withdrawn (Funding not secured.)
First Posted : October 28, 2009
Last Update Posted : April 6, 2016
|Condition or disease||Intervention/treatment|
|Parkinson's Disease||Drug: Levodopa (delivered intravenously)|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Determining the Natural History of Levodopa-Induced Dyskinesia (LID)|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
Drug: Levodopa (delivered intravenously)
One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
- Levodopa-Induced Dyskinesia [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01003002
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Kathryn Chung, MD||Oregon Health and Science University|